CAC
UTHR icon

Cowen and Company’s United Therapeutics UTHR Stock Holding History

Cowen and Company’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,342
Closed -$2.05M – 718
2023
Q4 		$2.05M Buy
+9,342
New +$2.15M 0.13% 112
2021
Q4 		– Sell
-9,780
Closed -$1.8M – 753
2021
Q3 		$1.8M Buy
+9,780
New +$1.93M 0.09% 106
2020
Q1 		– Sell
-17,742
Closed -$1.56M – 530
2019
Q4 		$1.56M Buy
+17,742
New +$1.56M 0.14% 68

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cowen and Company's UTHR Position: Q1 2024 in Review

Cowen and Company sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 9,342 shares — an estimated $2.05M sold.

Cowen and Company first reported a position in UTHR in Q4 2019 and held it in 3 quarters. The position peaked at $2.05M in Q4 2023. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

  • Cowen and Company reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 9,342 United Therapeutics shares in Q1 2024, an estimated $2.05M.
  • Cowen and Company first reported a position in United Therapeutics in Q4 2019 and held it in 3 quarters.
  • Cowen and Company's United Therapeutics position peaked at $2.05M in Q4 2023.
  • 525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.